Production of human cathepsins using Expi293™ mammalian cell expression system for off‐target activity of cysteine protease inhibitor screening
Protein Science · 2025
DOI: 10.1002/pro.70361 ↗At a glance
Journal article in Protein Science, 2025. Written by Zoe Turner and 9 co-authors. Institution: Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada. Major MEDLINE topics: Cysteine Proteinase Inhibitors, Cathepsins, Antiviral Agents. 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Alberta Innovation and Advanced Education Research Capacity Program, Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health Research Rapid Research.
Abstract (original language)
Following the SARS‐CoV‐2 pandemic, many direct‐acting antivirals targeting viral cysteine protease were developed. SARS‐CoV‐2, as well as other viruses, rely on cysteine proteases for their replication, suggesting future generations of antivirals targeting cysteine proteases will emerge. A major concern for these first‐generation drugs is the off‐target effects on host cysteine proteases. Therefore, screening for inhibitor specificity is a crucial step in antiviral drug development. Cathepsins are one of the most abundant human proteases, which have roles in maintaining cell health and are key to many physiological processes. Here we describe a general expression and purification protocol for cathepsins B, S, and L using the Expi293™ mammalian expression system. We characterized the glycosylation pattern and kinetic parameters of purified enzymes with commercially available cathepsin‐specific fluorogenic substrates and also established cathepsin inhibition screen assays. We tested specificity indices of peptidic inhibitors of SARS‐CoV‐2 M pro synthesized by our team and nirmatrelvir as a benchmark for all three cathepsins. Establishing a reliable cathepsin inhibition assay would assist with screening of newly developed cysteine protease inhibitors for off‐target activity within the scope of pandemic preparedness.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada.
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
- Department of Chemistry, University of Alberta, Alberta, Canada.
- Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, Alberta, Canada.
ORCID profiles: Elena Arutyunova, Duong T Bui, Ling Han, Lara K Mahal, John S Klassen
Funding
- Alberta Innovation and Advanced Education Research Capacity Program
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research Rapid Research
- Canada Excellence Research Chairs, Government of Canada
- Canada Foundation for Innovation
Cite
APA
Turner, Z., Arutyunova, E., Bui, D. T., Han, L., Kandadai, A. S., Bai, B., Young, H. S., Mahal, L. K., Klassen, J. S., & Lemieux, M. J. (2025). Production of human cathepsins using Expi293™ mammalian cell expression system for off‐target activity of cysteine protease inhibitor screening. Protein Science. https://doi.org/10.1002/pro.70361
Vancouver
Turner Z, Arutyunova E, Bui DT, Han L, Kandadai AS, Bai B, et al. Production of human cathepsins using Expi293™ mammalian cell expression system for off‐target activity of cysteine protease inhibitor screening. Protein Science. 2025. doi:10.1002/pro.70361
BibTeX
@article{Turner2025,
author = {Turner, Zoe and Arutyunova, Elena and Bui, Duong T and Han, Ling and Kandadai, Appan Srinivas and Bai, Bing and Young, Howard S and Mahal, Lara K and Klassen, John S and Lemieux, M Joanne},
title = {Production of human cathepsins using Expi293™ mammalian cell expression system for off‐target activity of cysteine protease inhibitor screening},
journal = {Protein Science},
year = {2025},
doi = {10.1002/pro.70361}
}
EUVIMED